VERIGRAFT
The company develops personalized tissue-engineered grafts by transforming donated allogeneic tissue into autologous-like tissue to prevent immune rejection. Its lead product, a personalized tissue-engineered vein (P-TEV), is currently entering Phase II/III clinical trials for the treatment of chronic venous insufficiency. This technology aims to eliminate the requirement for lifelong immunosuppressant drugs in patients receiving tissue transplants.
Visit websiteGothenburg, Sweden
Healthtech
Biotechnology
Regenerative Medicine
Funding summary
- Total raised
- €1.2M
- Funding rounds
- 1
Investors in VERIGRAFT
Investors on record for VERIGRAFT. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like VERIGRAFT?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors